KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash & Equivalents (2016 - 2026)

Amgen has reported Cash & Equivalents over the past 18 years, most recently at $12.0 billion for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 36.64% year-over-year to $12.0 billion; the TTM value through Mar 2026 reached $12.0 billion, up 36.64%, while the annual FY2025 figure was $9.1 billion, 23.75% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $12.0 billion at Amgen, up from $9.1 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $34.7 billion in Q3 2023 and troughed at $5.2 billion in Q2 2022.
  • A 5-year average of $13.4 billion and a median of $9.4 billion in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 558.24% in 2023 and later crashed 74.06% in 2024.
  • Year by year, Cash & Equivalents stood at $7.6 billion in 2022, then surged by 43.45% to $10.9 billion in 2023, then increased by 9.4% to $12.0 billion in 2024, then fell by 23.75% to $9.1 billion in 2025, then surged by 31.87% to $12.0 billion in 2026.
  • Business Quant data shows Cash & Equivalents for AMGN at $12.0 billion in Q1 2026, $9.1 billion in Q4 2025, and $9.4 billion in Q3 2025.